1. Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide)
- Author
-
A. H. Maurer, H. W. Strauss, James T. Symanowski, P. R. Ellis, R. N. Joyrich, R. T. Morris, N. P. Shah, W. A. Harb, R. W. Naumann, and J. M. Uszler
- Subjects
Adult ,Diagnostic Imaging ,medicine.medical_specialty ,Phases of clinical research ,Lesion ,chemistry.chemical_compound ,Folic Acid ,medicine ,Humans ,Folate Receptor 1 ,Molecular Targeted Therapy ,Vinca Alkaloids ,Aged ,Neoplasm Staging ,Ovarian Neoplasms ,Tomography, Emission-Computed, Single-Photon ,Vintafolide ,medicine.diagnostic_test ,business.industry ,Endometrial cancer ,Organotechnetium Compounds ,Hematology ,Middle Aged ,medicine.disease ,Radiography ,Clinical trial ,Oncology ,chemistry ,Folate receptor ,Response Evaluation Criteria in Solid Tumors ,Female ,Radiology ,medicine.symptom ,business ,Emission computed tomography - Abstract
This report examines (99m)Tc-etarfolatide imaging to identify the presence of folate receptor (FR) on tumors of women with recurrent/refractory ovarian or endometrial cancer and correlates expression with response to FR-targeted therapy (vintafolide).In this phase II, single-arm, multicenter study, patients with advanced ovarian cancer were imaged with (99m)Tc-etarfolatide before vintafolide treatment. Up to 10 target lesions (TLs) were selected based on Response Evaluation Criteria In Solid Tumors criteria using computed tomography scans. Single-photon emission computed tomography images of TLs were assessed for (99m)Tc-etarfolatide uptake as either FR positive or negative. Patients were categorized by percentage of TLs positive and grouped as FR(100%), FR(10%-90%), and FR(0%). Lesion and patient response were correlated with etarfolatide uptake.Forty-nine patients were enrolled; 43 were available for analysis. One hundred thirty-nine lesions were (99m)Tc-etarfolatide evaluable: 110 FR positive and 29 FR negative. Lesion disease control rate (DCR = stable or response) was observed in 56.4% of FR-positive lesions versus 20.7% of FR-negative lesions (P0.001). Patient DCR was 57%, 36%, and 33% in FR(100%), FR(10%-90%), and FR(0%) patients, respectively. Median overall survival was 14.6, 9.6, and 3.0 months in FR(100%), FR(10%-90%), and FR(0%) patients, respectively.Overall response to FR-targeted therapy and DCR correlate with FR positivity demonstrated by (99m)Tc-etarfolatide imaging.NCT00507741.
- Published
- 2014
- Full Text
- View/download PDF